Steve Worland

Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million. Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich,...